Posts by: Daniela Semedo, PhD

Daniela Semedo, PhD

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

September 29, 2016

FDA Approves Amjevita as Humira Biosimilar to Treat Psoriasis and Other Inflammatory Diseases

News

The U.S. Food and Drug Administration (FDA) has approved Amgen’s Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab, AbbVie) for use in multiple inflammatory diseases, including psoriasis. Amjevita is now approved ... Read more

September 13, 2016

Psoriatic Arthritis Patients’ Symptoms Improved with Otezla Treatments

News

Results from a Phase III clinical trial showed that treatment with Otezla (apremilast) led to clinical improvements in patients with psoriatic arthritis for up to 13 months, including signs and symptoms, ... Read more

August 29, 2016August 29, 2016

Penn State Dermatologist Debunks Common Myths About Psoriasis

News

Dr. Sara Ferguson, a dermatologist at Penn State Health, outlined in a recent communication various myths about psoriasis, ranging from it being contagious to patients having no treatment options beyond topical creams. ... Read more

August 26, 2016

Interim Results of Phase 2a Trial for Psoriasis Reported by Galectin; Focus Remains on NASH

News

Galectin Therapeutics recently reported interim data from an open-label exploratory Phase 2a study investigating its development-stage galectin-3 (gal-3) inhibitor, GR-MD-02, in patients with moderate to severe plaque psoriasis. In May, Galectin had ... Read more

August 11, 2016August 11, 2016

Coherus Reports Positive Initial Data in Ongoing Study of Humira Biosimilar to Treat Plaque Psoriasis

News

Coherus BioSciences recently reported that its ongoing Phase 3 pharmacokinetic and bioequivalence study comparing biosimilar CHS-1420, a candidate treatment for plaque psoriasis, to Humira (adalimumab) successfully met its 12-week endpoints. Specifically, the study demonstrated similarity ... Read more

August 8, 2016August 8, 2016

Psoriasis Linked to Social Anxiety and Depression in Study

News

Psoriasis is linked to depression, poor sleep quality, and anxiety interacting with and being around others, researchers from University Hospital Policlinico-Vittorio Emanuele in Italy reported. The findings were recently published in the International Journal ... Read more

August 4, 2016August 4, 2016

Sandoz Reports Biosimilar for Enbrel Effectively Treated Plaque Psoriasis in Phase 3 Study

News

Sandoz, a division of Novartis, reported that its clinical trial comparing the efficacy and the safety of GP2015, its biosimilar candidate to Enbrel (etanercept), met its primary endpoint — effectiveness ... Read more

August 1, 2016August 1, 2016

Moderate-to-Severe Psoriasis May Be Treated Using Mix of Biologic and Light Therapies

News

A combination of biologic and phototherapy treatments appear to be a viable clinical strategy for people with moderate-to-severe psoriasis who do not respond to either as monotherapy, according to a recent systematic review. ... Read more

July 14, 2016

FDA Panel Recommends Amgen’s ABP 501 as Biosimilar to Humira

News

The Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) recommends licensing Amgen’s ABP 501 as a biosimilar product to AbbVie’s FDA-approved Humira (adalimumab) for the treatment of patients with ... Read more

June 17, 2016

EU Grants Clinical Trial Approval for Plaque Psoriasis Phase 3 Study of ONS-3010 (Humira Biosimilar)

News

Cranbury, New Jersey-based Oncobiologics announced that its Phase 3 clinical strategy for ONS-3010 (Humira biosimilar) has been granted the first of its European Union (EU) clinical trial authorization (CTA) approvals, including Spain, Germany, and ... Read more